Emerald Mutual Fund Advisers Trust’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.3M Sell
67,054
-554
-0.8% -$95.7K 0.55% 75
2025
Q4
$12.3M Buy
67,608
+2,103
+3% +$294K 0.6% 76
2025
Q3
$7.96M Buy
65,505
+1,570
+2% +$177K 0.41% 90
2025
Q2
$6.67M Buy
+63,935
New +$6.77M 0.41% 91

Other funds holding AXSM

Emerald Mutual Fund Advisers Trust's AXSM Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its Axsome Therapeutics (AXSM) stake by 0.82% in Q1 2026, selling an estimated $95.7K and leaving 67,054 shares worth $11.3M. The position accounts for 0.55% of the portfolio, ranked #75.

Emerald Mutual Fund Advisers Trust first reported a position in AXSM in Q2 2025 and has held it in 4 quarters since. The position peaked at $12.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Emerald Mutual Fund Advisers Trust held 67,054 shares of Axsome Therapeutics worth $11.3M as of Q1 2026.
  • Emerald Mutual Fund Advisers Trust sold 554 Axsome Therapeutics shares in Q1 2026, an estimated $95.7K.
  • Axsome Therapeutics made up 0.55% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #75 holding.
  • Emerald Mutual Fund Advisers Trust first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Emerald Mutual Fund Advisers Trust's Axsome Therapeutics position peaked at $12.3M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.